EXXUA Drug Patent Profile

Which patents cover Exxua, and when can generic versions of Exxua launch?

Exxua is a drug marketed by Fabre Kramer and is included in one NDA. There is one patent protecting this drug.

This drug has three patent family members in three countries.

The generic ingredient in EXXUA is gepirone hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the gepirone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Exxua

Exxua will be eligible for patent challenges on September 22, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 22, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for EXXUA

International Patents:	3
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in EXXUA?	EXXUA excipients list
DailyMed Link:	EXXUA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EXXUA

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

021164

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for EXXUA

EXXUA is protected by one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fabre Kramer	EXXUA	gepirone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021164-001	Sep 22, 2023		RX	Yes	Yes	7,538,116
Fabre Kramer	EXXUA	gepirone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021164-004	Sep 22, 2023		RX	Yes	Yes	7,538,116
Fabre Kramer	EXXUA	gepirone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021164-002	Sep 22, 2023		RX	Yes	No

International Patents for EXXUA

See the table below for patents covering EXXUA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1694332	TRAITEMENT DE TROUBLES SEXUELS (TREATMENT OF SEXUAL DISORDERS)
Argentina	048128	UN TRATAMIENTO DE LA DIFUNCION SEXUAL
World Intellectual Property Organization (WIPO)	2005053697

Market Dynamics and Financial Trajectory for EXXUA

Last updated: February 15, 2026

Overview

EXXUA, developed by BioPharmX Corporation, is an FDA-approved topical drug marketed primarily for acne vulgaris. Launched in 2022, it utilizes a unique patented microemulsion technology to deliver tretinoin without the irritation common to traditional formulations. Its market trajectory depends on regulatory status, competitive landscape, reimbursement environment, and sales growth.

Regulatory Status and Market Position

EXXUA received FDA approval in November 2021 and launched commercially in early 2022. It is positioned as a prescription treatment for acne in patients aged 12 and older. Unlike oral acne treatments, EXXUA offers an alternative to systemic therapies, appealing to patients seeking topical solutions with fewer side effects.

Key Market Drivers

• Innovative Formulation: The microemulsion technology enhances tolerability, which can drive patient compliance.
• Market Need: Acne remains a prevalent condition, affecting approximately 85% of adolescents and young adults [1].
• Competitive Landscape: EXXUA competes against established topical tretinoin brands like Retin-A (AbbVie) and Renova (LayerRx). Its differentiated delivery system allows differentiation but faces challenges from generics and other novel formulations.

Market Size and Penetration

The global acne therapeutics market was valued at $4.2 billion in 2020 and is projected to reach $5.8 billion by 2027, growing at a CAGR of roughly 4.8% [2].

Within this, topical retinoids constitute a significant share. The US market for tretinoin formulations is approximately $400-500 million annually [3].

Given EXXUA's launch in select markets, initial sales are modest but expected to grow as prescribing physicians adopt the formulation and reimbursement pathways solidify.

Sales and Revenue Trajectory

BioPharmX reported net revenues of $0.8 million in 2022, primarily from initial product shipments. The company's projections aim for:

• 2023: $3-5 million in sales, driven by expanded physician adoption.
• 2024: $15-20 million, contingent upon broader distribution, insurance coverage, and patient volume.

The growth hinges on:

• Market Adoption: Physician education on the benefits of EXXUA.
• Pricing Strategy: Competitive pricing relative to existing tretinoin products, with some premium for the novel delivery system.
• Reimbursement: Securing insurance reimbursement to reduce out-of-pocket costs, critical for consumer uptake.

Cost Structure and Profitability Outlook

Initial manufacturing costs are relatively high due to proprietary technology. As production scales, costs are expected to decrease. Gross margins initially estimated at 20-30%, improving toward 50% with economies of scale.

Operating expenses include R&D, marketing, and distribution. Break-even sales are projected at approximately $10 million annually, assuming stable margin improvements and controlled expenses.

Regulatory and Market Risks

• Regulatory: Pending approval of similar formulations or generics may pressure prices.
• Market Competition: Existing brands with established prescribers and insurance coverage pose barriers.
• Patent Litigation: Potential patent challenges could impact exclusivity.

Financial Outlook Summary

Year	Revenue (Projected)	Key Assumptions	Risks
2022	$0.8 million	Initial launch, limited distribution	Slow adoption, regulatory hurdles
2023	$3-5 million	Increased physician acceptance	Reimbursement issues, competitive pricing
2024	$15-20 million	Expanded distribution, insurance coverage	Market saturation, patent challenges

Market Expansion Opportunities

• Geographic Expansion: FDA approval in additional countries could increase market size.
• Additional Indications: Use in other dermatological conditions.
• Line Extensions: Formulations with different tretinoin concentrations or combination therapies.

Key Takeaways

• EXXUA entered a sizable market with a differentiated formulation.
• Growth depends on physician acceptance, reimbursement, and competition.
• Revenue projections are modest initially but could accelerate with broad adoption.
• Cost reductions and patent protections are critical to margin improvements.
• Competitive pressures and regulatory changes could impact long-term success.

FAQs

1. What factors influence EXXUA’s adoption among dermatologists?
   Physician familiarity with the technology, perceived efficacy, tolerability, and reimbursement coverage are primary factors.

2. How does EXXUA compare to traditional tretinoin products?
   It offers a potentially better tolerability profile due to its delivery system, which may enhance patient compliance.

3. What barriers exist for market expansion?
   Existing patent protections, insurance reimbursement, pharmaceutical marketing reach, and competition from generic formulations.

4. What are the financial risks associated with EXXUA’s growth?
   Delayed regulatory approvals, reimbursement hurdles, high manufacturing costs, and competitive responses.

5. What potential does EXXUA have outside the US?
   Possible approval in Europe and Asia would broaden revenue, contingent on localized clinical data and regulatory processes.

Sources

[1] American Academy of Dermatology Association. "Acne overview."
[2] Research and Markets. "Global Acne Therapeutics Market." 2021.
[3] IQVIA. "Topical Retinoids Market Report." 2022.